High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer

Clinical Cancer Research

Volumn 3, Issue 2, 1997, Pages 193-197

  DeMagalhaes Silverman, Margarida ^a,b   Bloom, Elana ^a   Lembersky, Barry ^a   Lister, John ^a   Pincus, Steven ^a   Rybka, Witold ^a   Voloshin, Michael ^a   Wilson, John ^a   Ball, Edward ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CARBOPLATIN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; THIOTEPA;

ADULT; ARTICLE; AUTOGRAFT; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKAPHERESIS; METASTASIS; NEUTROPENIA; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MIDDLE AGED; PLATELET COUNT; THIOTEPA; TREATMENT OUTCOME;

EID: 0031029404     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Antman, K. H. Dose-intensive therapy in breast cancer. In: J. O. Armitage and K. H. Antman (eds.), High-Dose Cancer Therapy: Pharmacology, Hematopoietins, and Stem Cells, pp. 701-718. Baltimore: Williams & Wilkins, 1992.
2. Ragaz, J., and Ariel, I. M. Future and development aspects of high-risk breast cancer therapy. In: J. Ragaz and I. M. Ariel (eds.), High-Risk Breast Cancer Therapy, pp. 493-510. Berlin: Springer-Verlag, 1991.
3. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
4. Antman, K., Ayash, L., Elias, A., Wheeler, C. Hunt, M., Eder, J. P., Teicher, B. A., Critchlow, J., Bibbo, J., Schnipper, L. E., and Frei, E., III. A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autologous support in women with measurable advanced breast cancer responding to standard dose therapy. J. Clin. Oncol., 10: 102-110, 1992.
5. Williams, S. F., Gilewski, T., Mick, R., and Bitran, J. D. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J. Clin. Oncol., 10: 1743-1747, 1992.
6. Somlo, G., Doroschow, J. J., Forman, S. J., Leong, L. A., Margolin, K. A., Morgan, R. J., Jr., Raschko, J. W., Akman, S. A., Ahn, C., and Sniecinski, I. High dose cisplatin. etoposide and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer (Phila.), 73: 125-134, 1994.
7. Kennedy, M. J., Beveridge, R. A., Rowley, S. D., Gordon, G. B., Abeloff, M. D., and Davidson, N. E. High dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J. Natl. Cancer Inst., 83: 920-926, 1991.
8. Pinedo, H. M. Dose effect relationship in breast cancer. Ann. Oncol., 4: 351-357, 1993.
9. Peters, W. P., Shpall, E. J., Jones, R. B., Olsen, G. A., Bast, R. C., Gockerman, J. P., and Moore, J. O. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin. Oncol., 6: 1368-1376, 1988.
10. Gianni, A. M., Bregni, M., Sienna, S., Orazi, A., Stern, A. C., Gandola, L., and Bonadonna, G. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J. Clin. Oncol., 8: 768-778.
11. Patrone, F., Ballestrero, A., Balleari, E., Bogliolo, F., Brema, F., Ferrando, F., Ghio, R., and Timitilli, S. High dose cyclophosphamide followed by GM-CSF is a safe and effective procedure for the recruitment of trilineage circulating progenitor cells. Haematologica, 77: 457-462, 1992.
12. Elias, A. D., Ayash, L., Anderson, K. C., Hunt, M., Wheeler, C., Schwartz, G., Tepler, I., Mazanet, R., Lynch, C., Pap, S., Palaez, J., Reich, E., Critchlow, J., Demetri, G., Bibbo, J., Schnipper, L., Griffin, J. D., Frei, E., III, and Antman, K. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematopoietic support after high-dose intensification for breast cancer. Blood, 79: 3036-3044, 1992.